Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabestomig
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Sabestomig is a bispecific monoclonal antibody under development by AstraZeneca. It targets both programmed cell death protein 1 (PD-1) and T cell immunoglobulin mucin-3 (TIM-3), two immune checkpoint proteins involved in the regulation of immune responses. By simultaneously inhibiting PD-1 and TIM-3, sabestomig aims to reinvigorate T-cell activity against tumors or inflammatory processes that are resistant to single checkpoint blockade. The drug is being investigated for use in relapsed/refractory classical Hodgkin lymphoma, Crohn’s disease (regional enteritis), and various solid tumors including non-small cell lung cancer and gastric/gastroesophageal junction adenocarcinoma. Sabestomig is administered intravenously[1][4][5][7].
- Other names
- sabestomig
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on sabestomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabestomig.